Ardelyx Stock Price, News & Analysis

Ardelyx (NASDAQ: ARDX) announced that President and CEO Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.

The session will be available via a public webcast on Ardelyx's Events and Presentations webpage, and a replay will be posted on the Ardelyx website for 30 days after the event.

Ardelyx (Nasdaq: ARDX) reported Q3 2025 total revenue $110.3M and product revenue of $105.5M. IBSRELA delivered $78.2M in Q3, up 92% YoY, and guidance for full‑year 2025 IBSRELA revenue was raised to $270–275M. XPHOZAH generated $27.4M in Q3, up 9% QoQ but down versus prior year following the loss of Medicare Part D coverage effective Jan 1, 2025. Cash, cash equivalents and short‑term investments were $242.7M as of Sept 30, 2025. The company began development of RDX10531, a next‑generation NHE3 inhibitor, and expects to support an IND submission in 2026.

Q3 net loss was $1.0M; R&D was $18.1M and SG&A was $83.6M.

Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of IBSRELA (tenapanor) at the ACG 2025 Annual Meeting (Oct 28, 2025). Key findings include high patient-reported treatment satisfaction (88%), reported improvements in constipation (95%), bloating (75%) and abdominal pain (84%), and 76% saying IBSRELA is better than prior IBS-C medications. Phase 3 T3MPO-1/2 post-hoc analyses show clinically meaningful bloating reduction as early as week one and sustained benefit. An EHR study found reductions in GI visits and patient portal messaging after tenapanor initiation among high healthcare resource users, suggesting potential to lower HCRU.

Ardelyx (Nasdaq: ARDX) announced four poster presentations supporting XPHOZAH (tenapanor) at the American Society of Nephrology Kidney Week, November 5–9, 2025 in Houston.

XPHOZAH is described as the first and only phosphate absorption inhibitor approved by the U.S. FDA to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy for patients with inadequate response or intolerance to phosphate binders; it is dosed as a single tablet twice daily.

Four posters will present real-world effectiveness, treatment satisfaction, bowel-movement benefits, and trends in etelcalcetide use and parathyroidectomy rates on November 6–7, 2025, plus an Exhibitor Spotlight on November 7, 2025 from 11:00–11:45 AM CST.

Ardelyx (Nasdaq: ARDX) will report third quarter 2025 financial results and provide a business update on Thursday, October 30, 2025 at 4:30 p.m. ET. The company will host a live conference call and simultaneous webcast accessible from the Investors section of its website at www.ardelyx.com. Domestic dial-in is (877) 346-6112 and international dial-in is (848) 280-6350. The live webcast will be archived and available for replay for 30 days after the call.

Ardelyx (Nasdaq: ARDX) announced the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner brings more than 30 years of corporate finance and operations experience and served most recently as VP and CFO of Johnson & Johnson Innovative Medicine North America, where she led financial strategies for a $36 billion commercial business. She is a CPA and CMA with a BS in Accounting and an MBA. Hohenleitner will assume the role following Ardelyx’s third quarter 2025 financial reporting; current CFO and COO Justin Renz will continue in his role through the filing of Ardelyx’s Form 10-Q.

This leadership change is positioned to support Ardelyx’s commercial expansion and long-term growth strategy while the company executes near-term financial reporting and transition steps.

Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has announced its participation in four major investor conferences in September 2025:

• Citi Biopharma Back to School Summit in Boston (Sept 3)
• Cantor Global Healthcare Conference in New York (Sept 4)
• Morgan Stanley 23rd Annual Global Healthcare Conference in New York (Sept 8)
• H.C. Wainwright 27th Annual Global Investment Conference in New York (Sept 9)

Live webcasts of the fireside chats and presentations will be available on Ardelyx's investor relations website, with replays accessible for 30 days after each event.

Ardelyx (NASDAQ:ARDX) announced significant changes to its Executive Leadership Team. The company appointed Edward Conner, M.D. as Chief Medical Officer, bringing over 20 years of experience in clinical development and regulatory approval. John Bishop, Ph.D. was named to the newly created position of Chief Technical Operations Officer, contributing 30 years of technical operations expertise.

Additionally, Justin Renz, the current Chief Financial and Operations Officer, will be departing the company by the end of 2025 or upon the successful transition to a new CFO. These changes are part of Ardelyx's strategic positioning for its next growth phase, following recent appointments including Mike Kelliher as CBO, Laura Williams as CPO, and Jamie Brady as CHRO.

Ardelyx (NASDAQ:ARDX) reported strong Q2 2025 financial results, with total revenue of $97.7 million, representing a 33% year-over-year growth. The company's flagship products showed significant performance: IBSRELA generated $65.0 million in net sales (84% YoY growth) and XPHOZAH contributed $25.0 million.

Key financial highlights include a strong cash position of $238.5 million as of June 30, 2025. The company raised its 2025 IBSRELA revenue guidance to $250-$260 million. Despite revenue growth, Ardelyx reported a net loss of $19.1 million ($0.08 per share) for Q2 2025.

Notable developments include securing an option to draw additional debt of $100 million through SLR Investment Corp. and key executive appointments including Mike Kelliher as Chief Business Officer and James P. Brady as Chief Human Resources Officer.